Cellectar Biosciences
CLRB
11 hedge funds and large institutions have $593K invested in Cellectar Biosciences in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
44% more capital invested
Capital invested by funds: $413K → $593K (+$180K)
0% more funds holding
Funds holding: 11 → 11 (0)
0% less ownership
Funds ownership: 0.03% → 0.02% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$6.09K |
| 2 |
AWM
AllSquare Wealth Management
Albany,
New York
|
+$609 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$26.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9K |
| 3 |
Renaissance Technologies
New York
|
-$609 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFM
1
Sphera Funds Management
Tel Aviv,
Israel
| $206K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $133K | -$609 | -1 | -0.5% |
|
|
3
Morgan Stanley
New York
| $125K | -$26.2K | -43 | -20% |
|
|
4
Citadel Advisors
Miami,
Florida
| $42K | +$6.09K | +10 | +20% |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $39K | – | – | – |
|
6
Dimensional Fund Advisors
Austin,
Texas
| $24K | – | – | – |
|
|
AIC
7
AWM Investment Company
New York
| $11K | – | – | – |
|
8
US Bancorp
Minneapolis,
Minnesota
| $7K | – | – | – |
|
|
LTFS
9
Ladenburg Thalmann Financial Services
Miami,
Florida
| $5K | – | – | – |
|
|
SIM
10
Sonora Investment Management
Tucson,
Arizona
| $1K | – | – | – |
|
|
KFS
11
Kelly Financial Services
Braintree,
Massachusetts
| $63 | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$9K | -19 | Closed |
|
|
AWM
13
AllSquare Wealth Management
Albany,
New York
| – | +$609 | +1 | New |
|
CLRB Hedge Fund Activity: Q1 2019 in Review
11 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2019, worth a combined $593K — up 44% from $413K a quarter earlier.
Fund positioning in CLRB was balanced in Q1 2019: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $6.09K. The largest seller was Morgan Stanley, cutting an estimated $26.2K.
- 11 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $593K of Cellectar Biosciences stock for Q1 2019, up 44% quarter-over-quarter.
- 1 fund opened new Cellectar Biosciences positions in Q1 2019 and 1 closed out, a net change of 0 holders.
- The largest Cellectar Biosciences buyer in Q1 2019 was Citadel Advisors, an estimated $6.09K added.
- The largest Cellectar Biosciences seller in Q1 2019 was Morgan Stanley, an estimated $26.2K sold.
Based on aggregated 13F filings for Q1 2019.